Scarica l'app Stockscreener
233.91
1.12%
-2.65
Dopo l'orario di chiusura:
233.00
-0.91
-0.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
Can AbbVie Inc. stock outperform in 2025 bull marketMarket Activity Report & Real-Time Volume Spike Alerts - newser.com
Why AbbVie Inc. stock is in analyst buy zoneTrade Entry Summary & Technical Pattern Alert System - newser.com
AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit - MSN
Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance - MSN
AbbVie updates 2025 earnings guidance to reflect $2.7 billion IPR&D expense - Investing.com
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit - Reuters
AbbVie (ABBV) Projects Lower Q3 Earnings Due to IPR&D Costs - GuruFocus
AbbVie (ABBV) Anticipates Financial Impact from Third Quarter Ex - GuruFocus
ABBV Stock Outlook Revised for FY25 - GuruFocus
ABBV Surpasses Earnings Expectations with Strong Q3 Performance - GuruFocus
AbbVie expects $2.7 billion R&D charge in third quarter - The Mighty 790 KFGO
AbbVie sees negative Q3, full-year impact from IPR&D and milestones expense - MSN
AbbVie Says $2.7 Billion in Costs Seen Cutting Q3 EPS by $1.50 - MarketScreener
AbbVie expects $2.7 billion R&D charge in third quarter, lowers annual profit forecast - MarketScreener
AbbVie sees $1.50 per share unfavorable impact in Q3 from milestones expense - TipRanks
AbbVie expects Q3 earnings to include $2.7 billion IPR&D expenseSEC filing - MarketScreener
AbbVie reports $2.7 billion IPR&D expense to impact Q3 earnings - StreetInsider
St Louis Financial Loads Up on AbbVie (ABBV) With 14,600 Shares Buy - The Globe and Mail
What drives AbbVie Inc stock priceReal Estate Investment Trusts & High Return Capital Strategies - earlytimes.in
B of A Securities Maintains AbbVie (ABBV) Neutral Recommendation - Nasdaq
AbbVie: Wins Accumulating While We Wait For Next BD Steps (NYSE:ABBV) - Seeking Alpha
TD Cowen Adjusts Price Target on AbbVie to $280 From $250, Maintains Buy Rating - MarketScreener
Bernstein Remains a Hold on AbbVie Inc. (ABBV) - MSN
Can AbbVie Inc. stock surprise markets with earnings2025 Technical Overview & Technical Buy Zone Confirmation - newser.com
AbbVie invests $70M in Worcester facility, and other life sciences news - The Business Journals
What to do if you’re stuck in AbbVie Inc.Portfolio Risk Report & Daily Chart Pattern Signal Reports - newser.com
Why AbbVie Inc. stock could be next leader2025 Market WrapUp & Safe Entry Point Identification - newser.com
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why - sharewise.com
Bain Set to Face Claims Over Cerevel Trades Before AbbVie Sale - Bloomberg Law News
Allergy Treatment Global Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, ALK - PharmiWeb.com
AbbVie (ABBV) Kidney Disease Therapy Garners FDA Fast Track Stat - GuruFocus
AbbVie’s Phase 2 HIV Study Completion: Potential Market Impact - TipRanks
AbbVie to Host Third-Quarter 2025 Earnings Conference Call - Yahoo Finance
AbbVie downgraded to Hold from Buy at HSBC (yesterday) - TipRanks
AbbVie (ABBV) Surges on Expansion and Industry Developments - GuruFocus
Why AbbVie Stock Cruised to an Almost 6% Gain Today - Yahoo Finance
AbbVie (ABBV) Downgraded by HSBC, Shares Continue to Climb - GuruFocus
Why AbbVie (ABBV) Stock Is Trading Up Today - Yahoo Finance
AbbVie downgraded at HSBC due to limited upside - MSN
AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability - msn.com
HSBC Downgrades AbbVie (ABBV) Rating to Hold on October 1, 2025 - GuruFocus
AbbVie begins $70M Massachusetts expansion as pharmaceutical tariffs kick in - Crain's Chicago Business
AbbVie Stock Is Just What the Doctor Ordered - MSN
AbbVie breaks ground on $70m US biologics site amid Trump pressure - Pharmaceutical Technology
AbbVie Stock Is Just What The Doctor Ordered - Barchart.com
2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi - Yahoo Finance
ABSSSI Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Glenmark Pharma, Melinta Therapeutics, Sandoz Inc, Paratek Pharma, AbbVie Inc., Allergan PLC, Merck & Co. Inc., Pfizer - The Globe and Mail
Natrelle® Awarded Supplier Agreement from Vizient - PR Newswire
Big pharma firms announce direct-to-consumer sales and price cuts in U.S. - Reuters
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever - The Motley Fool
AbbVie (ABBV) Invests $70M in Worcester Expansion to Boost Biolo - GuruFocus
AbbVie starts construction on $70M R&D, manufacturing center expansion - Seeking Alpha
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge - FinancialContent
AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know - The Globe and Mail
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S. - Investing News Network
AbbVie (ABBV) Enhances U.S. Biologics Manufacturing with $70M Ex - GuruFocus
AbbVie begins $70 million expansion of Worcester biologics facility By Investing.com - Investing.com Canada
$70M Biologics Expansion: AbbVie Boosts U.S. Manufacturing for Oncology & Immunology Medicines - Stock Titan
Elahere UK list price should match USA or it won’t be launched, AbbVie warns - The Pharma Letter
1.43%
0.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):